AbbVie, Genentech Scoop Up FDA Approval for Leukemia Drug Venclexta

The FDA has given the green light to the chronic lymphocytic leukemia treatment Venclexta, which will be marketed by AbbVie and Roche’s Genentech unit.
Source: Drug Industry Daily